Trial Profile

A Phase 2, Multicenter, Double-blind, Two-arm Study of Subcutaneous RO7790121 for the Treatment of Subjects With Moderate to Severe Active Crohn's Disease

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Sep 2024 Trial focus changed from TU to AR. Primary endpoint ' Proportion of participants achieving clinical remission by CDAI Induction of Clinical Remission by CDAI [Time Frame: Week 14]' to 'Incidence of Treatment-Emergent Adverse Events (TEAE), Serious Adverse Events (SAE) and AE Leading to Discontinuation time-frame: Until end of study, approximately 5 years'.
27 Sep 2024 Planned End Date changed from 15 Dec 2025 to 31 Dec 2030.
27 Sep 2024 Planned End Date changed from 15 Dec 2025 to 31 Dec 2030.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com